Literature DB >> 19156409

Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma.

Patrick Veit-Haibach1, Florian M Vogt, Robert Jablonka, Hilmar Kuehl, Andreas Bockisch, Thomas Beyer, Gerlinde Dahmen, Sandra Rosenbaum, Gerald Antoch.   

Abstract

PURPOSE: To evaluate the diagnostic accuracy of contrast-enhanced FDG-PET/CT (ce-PET/CT), PET-only, and CT-only in patients with newly diagnosed and resected cutaneous malignant melanoma.
METHODS: A final group of 56 patients (mean age 62 years, range 23-86 years; 29 women, 27 men) were staged with ce-PET/CT after resection of the primary tumour. Histopathology as well as clinical follow-up (mean 780 days, range 102-1,390 days) served as the standards of reference. Differences between the staging modalities were tested for statistical significance with McNemar's test.
RESULTS: All imaging procedures provided low sensitivities in the detection of lymph nodes (sensitivity N-stage: PET/CT and PET-only 38.5%; CT-only 23.1%) and distant metastases (sensitivity M-stage: PET/CT 41.7%, PET-only 33.3%, CT-only 25.0%) in initial staging after resection of the primary tumour. No statistically significant differences were detected between the imaging procedures (p > 0.05). PET/CT resulted in an alteration in further treatment in two patients compared to PET-only and in four patients compared to CT-only.
CONCLUSION: All imaging modalities had a low sensitivity on initial staging of patients with malignant melanoma. Thus, close patient follow-up must be considered mandatory.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19156409     DOI: 10.1007/s00259-008-1049-x

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  26 in total

1.  Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology.

Authors:  Thomas Beyer; Gerald Antoch; Todd Blodgett; Lutz F Freudenberg; Tim Akhurst; Stephan Mueller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-12       Impact factor: 9.236

2.  Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma.

Authors:  D J Macfarlane; V Sondak; T Johnson; R L Wahl
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

3.  Equivalence test and confidence interval for the difference in proportions for the paired-sample design.

Authors:  T Tango
Journal:  Stat Med       Date:  1998-04-30       Impact factor: 2.373

4.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

5.  Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system.

Authors:  C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

6.  Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.

Authors:  Jeffrey D Wagner; Donald Schauwecker; Darrell Davidson; Theodore Logan; John J Coleman; Gary Hutchins; Charlene Love; Stacie Wenck; Joanne Daggy
Journal:  Cancer       Date:  2005-08-01       Impact factor: 6.860

7.  Positron emission tomography scanning in malignant melanoma.

Authors:  D S Tyler; M Onaitis; A Kherani; A Hata; E Nicholson; M Keogan; S Fisher; E Coleman; H F Seigler
Journal:  Cancer       Date:  2000-09-01       Impact factor: 6.860

8.  S-100B and FDG-PET/CT in therapy response assessment of melanoma patients.

Authors:  Klaus Strobel; Jeannine Skalsky; Hans C Steinert; Reinhard Dummer; Thomas F Hany; Ujwal Bhure; Burkhardt Seifert; Marisol Pérez Lago; Helen Joller-Jemelka; V Kalff
Journal:  Dermatology       Date:  2007       Impact factor: 5.366

Review 9.  PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies.

Authors:  Heiko Schöder; Steven M Larson; Henry W D Yeung
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

10.  Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes.

Authors:  C L Day; A J Sober; R A Lew; M C Mihm; T B Fitzpatrick; A W Kopf; M N Harris; S L Gumport; J W Raker; R A Malt; F M Golomb; A B Cosimi; W C Wood; P Casson; S Lopransi; F Gorstein; A Postel
Journal:  Cancer       Date:  1981-03-01       Impact factor: 6.860

View more
  13 in total

Review 1.  Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review.

Authors:  Maria Danielsen; Liselotte Højgaard; Andreas Kjær; Barbara Mb Fischer
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-12-15

2.  The value of 18F-FDG-PET/CT imaging for sinonasal malignant melanoma.

Authors:  S K Haerle; M B Soyka; D R Fischer; K Murer; K Strobel; G F Huber; D Holzmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-06-29       Impact factor: 2.503

3.  Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis.

Authors:  Yan Xing; Yulia Bronstein; Merrick I Ross; Robert L Askew; Jeffrey E Lee; Jeffrey E Gershenwald; Richard Royal; Janice N Cormier
Journal:  J Natl Cancer Inst       Date:  2010-11-16       Impact factor: 13.506

4.  PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT.

Authors:  Thomas Pfluger; Henriette Ingrid Melzer; Vera Schneider; Christian La Fougere; Eva Coppenrath; Carola Berking; Peter Bartenstein; Mayo Weiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

5.  Assessment of pulmonary melanoma metastases with 18F-FDG PET/CT: which PET-negative patients require additional tests for definitive staging?

Authors:  Marius E Mayerhoefer; Helmut Prosch; Christian J Herold; Michael Weber; Georgios Karanikas
Journal:  Eur Radiol       Date:  2012-06-01       Impact factor: 5.315

6.  Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma.

Authors:  Tiefu Chen; Jie Zhu
Journal:  Med Oncol       Date:  2009-11-17       Impact factor: 3.064

7.  Lymph Node Micrometastases and In-Transit Metastases from Melanoma: In Vivo Detection with Multispectral Optoacoustic Imaging in a Mouse Model.

Authors:  Volker Neuschmelting; Hannah Lockau; Vasilis Ntziachristos; Jan Grimm; Moritz F Kircher
Journal:  Radiology       Date:  2016-05-04       Impact factor: 11.105

Review 8.  Intraoperative mapping of sentinel lymph node metastases using a clinically translated ultrasmall silica nanoparticle.

Authors:  Michelle S Bradbury; Mohan Pauliah; Pat Zanzonico; Ulrich Wiesner; Snehal Patel
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-12-10

9.  18F-FDG PET/CT Imaging in an Unusual Case of Cutaneous Melanoma Arising From Congenital Melanocytic Nevus in a Two-year-old Girl

Authors:  Seval Erhamamcı; Mehmet Reyhan; Nebil Bal; Neşe Torun; Ali Fuat Yapar
Journal:  Mol Imaging Radionucl Ther       Date:  2021-06-03

Review 10.  F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review.

Authors:  Milly A Schröer-Günther; Robert F Wolff; Marie E Westwood; Fülöp J Scheibler; Christoph Schürmann; Brigitta G Baumert; Stefan Sauerland; Jos Kleijnen
Journal:  Syst Rev       Date:  2012-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.